A study of profile of ventilator-associated pneumonia in children in Punjab.
OBJECTIVE
To determine incidence, related factors, outcome, bacterial organisms and their sensitivity patterns with regard to ventilator-associated pneumonia (VAP) in children.


METHODS
Level III PICU of a tertiary care center.


METHODS
Prospective cohort study.


METHODS
Children in the age group of 1 month to 15 years, admitted to the pediatric intensive care unit requiring ventilatory support (V.I.P.BIRD infant-Pediatric ventilator) for at least 48 h. Clinical criteria used to define VAPs were the same as used by and Elward et al. and Salata et al.


RESULTS
Forty patients met the inclusion criteria and 8 (20%) had VAP. The risk factor significantly related with development of VAP was the use of H(2) blockers (Ranitidine) for >2 days. All other related factors were not significantly related to occurrence of VAP.


CONCLUSIONS
Use of H(2) blockers (Ranitidne) is associated with higher incidence of VAP in children.
Sharma
Harsh
H
Department of Pediatrics, Indira Gandhi Memorial Hospital, Male, Maldives. dr_harsh75@yahoo.co.in
Singh
Daljit
D
Pooni
Puneet
P
Mohan
Urmil
U
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003428:Cross Infection / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006635:Histamine H2 Antagonists / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D007194:India; D007223:Infant; D015278:Intensive Care Units, Pediatric / Q000706:statistics & numerical data*; D008297:Male; D053717:Pneumonia, Ventilator-Associated / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology; D011446:Prospective Studies; D011899:Ranitidine / Q000009:adverse effects; D012307:Risk Factors; D012122:Ventilators, Mechanical / Q000009:adverse effects* / Q000382:microbiology
D006635:Histamine H2 Antagonists; D011899:Ranitidine